AstraZeneca's Brilinta has been found to reduce cardiovascular events in patients with coronary heart disease and diabetes but no prior heart attack or stroke.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.